How do I check if a biologic distributor is registered with the FDA?

You can search the FDA Human Cell and Tissue Establishment Registration System (HCTERS) public database online. Enter the distributor or manufacturing facility name to review their active establishment registration status and specific authorized tissue handling functions.

What is the difference between FDA registration and FDA approval for biologics?

Establishment registration under 21 CFR Part 1271 indicates that a tissue facility has registered its operations with the FDA and adheres to donor screening and tissue practices. Registration does not constitute formal pre-market clearance or approval, which is required only for specific drug or drug-classified biologic products.

Why is state licensing necessary if a distributor has FDA registration?

While the FDA regulates federal tissue safety and establishment registration, individual state health departments and medical boards govern wholesale distribution within their jurisdictions. Distributors must maintain active state-level licenses to legally ship tissue products to your clinical practice.

How long should a practice retain tissue tracking records and CoAs?

Practices should retain Certificates of Analysis, donor eligibility summaries, and tissue tracking logs for at least ten years beyond the administration date, or in accordance with state medical record retention laws. This ensures full audit readiness for clinical and regulatory reviews.

Verifying FDA Tissue Registration & Biologic Licensing

Verifying FDA tissue bank registration and state licensing for biologic distributors requires cross-referencing a vendor's FDA Establishment Identifier (FEI) in the HCTERS database with active state medical board wholesale distribution licenses. Integrating this step-by-step verification into routine procurement protocols protects clinical integrity when sourcing biologics like amniotic and cord blood allografts. Below is the standardized inspection sequence practice managers can implement to audit distributor credentials and streamline vendor onboarding.

Why Biologic Regulatory Compliance Matters for Medical Practices

In regenerative medicine, procuring biologics—such as umbilical cord tissue, amniotic allografts, platelet-rich plasma (PRP) systems, and autologous cellular therapies—requires strict adherence to regulatory standards. The U.S. Food and Drug Administration (FDA) regulates human cells, tissues, and cellular and tissue-based products (HCT/Ps) under 21 CFR Part 1271. These federal guidelines dictate establishment registration, donor screening, infectious disease testing, and Current Good Tissue Practice (cGTP).

When practice administrators fail to audit the compliance status of their biologic distributors, the practice assumes significant operational, financial, and legal risk. Administering improperly sourced or unapproved tissue products can result in sudden product recalls, medical malpractice exposure, loss of medical licensing, and exclusion from commercial or federal reimbursement frameworks. Working exclusively with credentialed vendors who distribute compliant biologics ensures that clinical safety aligns seamlessly with administrative risk management.

Step-by-Step Guide: Verifying FDA Tissue Bank Registration and State Licensing

To ensure every biologic product delivered to your clinical facility complies with state and federal laws, implementation of a multi-step verification process prior to issuing purchase orders is critical.

1. Query the FDA HCTERS Database

The FDA maintains the Human Cell and Tissue Establishment Registration System (HCTERS), a public database listing all registered tissue establishments.

Visit the official FDA HCTERS online portal.
Search by the distributor’s business name, manufacturing facility name, or FEI (Facility Establishment Identifier) number.
Verify that the establishment’s registration status is active and listed as "Registered" rather than "Terminated" or "Inactive."
Confirm the specific biological activities authorized, such as recovering, donor screening, processing, storing, or distributing HCT/Ps.

2. Verify State Wholesale Drug and Tissue Licensing

Federal registration alone is insufficient for legal distribution. States independently regulate the wholesale distribution of prescription medical products and human tissue within their borders.

Request a copy of the distributor's state wholesale distributor license or tissue bank permit for your state.
Cross-reference the license number with your state's Department of State Health Services (DSHS), Board of Pharmacy, or Medical Licensing Board.
Ensure the distributor holds valid licenses in both their home state (point of shipment) and your practice’s home state (point of delivery).

3. Review Lot-Specific Certificates of Analysis and Donor Eligibility

Every shipment of human tissue or biologic products must be accompanied by comprehensive quality control documentation.

Confirm that each lot includes a Certificate of Analysis (CoA) verified by a qualified medical director or tissue bank director.
Verify that donor screening protocols comply with FDA guidance for communicable disease testing, including HIV, Hepatitis B, Hepatitis C, and Syphilis.
Ensure terminal sterilization validation protocols are clearly documented where applicable.

4. Audit Cold-Chain Storage and Logistics

Biologic products require continuous temperature monitoring to maintain structural integrity and viability.

Confirm that the distributor utilizes validated cold-chain logistics, such as calibrated cryogenic or dry-ice shipping containers.
Ensure shipments include integrated temperature indicators or data loggers to verify that temperature thresholds were maintained throughout transit.

Vendor Verification Checklist for Practice Administrators

Administrators should incorporate the following checklist into their standard procurement and vendor onboarding Standard Operating Procedures (SOPs):

[ ] Active FDA Registration: FEIN/HCTERS registration verified and renewed annually.
[ ] State Licensing: Valid state tissue bank or wholesale distributor license confirmed with state authorities.
[ ] Donor Eligibility Documentation: Complete summary of donor records and infectious disease testing provided with every lot.
[ ] Sterilization Verification: Certificate of Analysis confirming sterility testing or validation protocols.
[ ] Logistics Integrity: Documented cold-chain process with continuous temperature monitoring during transit.
[ ] Traceability Protocols: Clear procedures for product tracking from donor lot to patient chart.
[ ] Recall Preparedness: Written recall notification procedures and dedicated quality assurance contacts.

Practice managers seeking additional clarity on regulatory frameworks can explore our detailed regulatory guides in our publications section.

Clinical vs. Operational Perspectives on Biologic Procurement

Successfully integrating regenerative therapies requires alignment between clinical providers and administrative staff. Both roles evaluate vendors through distinct yet complementary lenses.

The Clinical Perspective: Patient Safety and Tissue Viability

For physicians, orthopedists, pain management specialists, and aesthetic providers, clinical efficacy and patient safety are paramount. Clinicians rely on distributors to provide sterile, non-immunogenic tissue allografts with consistent structural characteristics. When a physician administers an allograft, they trust that the donor screening and tissue processing standards prevent infectious transmission and adverse host reactions. Reviewing CoAs and verifying donor eligibility gives clinicians confidence in the therapies they deliver at the point of care.

The Operational Perspective: Risk Management and Overhead Control

For practice managers and procurement administrators, vendor verification centers on risk mitigation, cost control, and workflow integration. Purchasing non-compliant tissue can expose the clinic to catastrophic legal claims and severe regulatory fines. Furthermore, inconsistent supply chains cause scheduling delays, wasted administrative hours tracking missing documentation, and inventory loss due to improper cold-chain management. Establishing vetted vendor relationships streamlined for who we serve stabilizes overhead and protects the practice's long-term financial health.

What This Means for Your Practice

Transitioning from informal vendor selection to a rigorous compliance-first procurement strategy safeguards your practice against regulatory scrutiny while streamlining clinical workflows.

To optimize your procurement protocols immediately, practice managers should take the following steps:

Audit Existing Inventory: Review current biologic supplies and compile a master list of all tissue manufacturers and distributors.
Request Full Compliance Binders: Require all active vendors to submit updated FDA registration numbers, state licenses, and sample CoAs.
Standardize Intake SOPs: Establish a protocol where clinical staff match lot numbers, expiration dates, and temperature indicators upon delivery before placing products into inventory.
Archive Documentation: Store all CoAs and tissue tracking logs in a centralized, secure digital repository accessible for medical audits.

For answers to common operational questions regarding procurement, visit our faq page.

Strengthening Your Biologic Supply Chain

Navigating the complex regulatory landscape of regenerative medicine requires a dedicated partner committed to compliance, transparency, and product quality. At Dallas Regenerative Solutions, we prioritize regulatory integrity across our full line of biologics, devices, and clinical supplies.

To learn how we support medical practices with compliant biologic distribution and seamless operational support, contact our compliance team today for a comprehensive consultation.